<DOC>
	<DOC>NCT00425178</DOC>
	<brief_summary>FGF-1 is being used for the treatment of patients with diabetic or venous stasis ulcers. Procedure includes topical administration of FGF-1 or placebo and evaluation of safety, pharmacokinetics, and wound improvement.</brief_summary>
	<brief_title>FGF-1 for Topical Administration for the Treatment of Diabetic or Venous Stasis Ulcers</brief_title>
	<detailed_description>Patients meeting eligibility criteria will be randomized to receive topical administration of either FGF-1 or placebo. Patients will be evaluated at days 1 and 7, post-treatment for safety, pharmacokinetics, and wound healing.</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Postphlebitic Syndrome</mesh_term>
	<mesh_term>Postthrombotic Syndrome</mesh_term>
	<mesh_term>Varicose Ulcer</mesh_term>
	<criteria>Eligibility Criteria: Informed consent Female patients postmenopausal, sterilized, or on adequate birth control Fullthickness lower extremity diabetic or venous statis ulcers of specific target size and of at least 8 weeks but no more than 1 year duration Target ulcer freshly debrided at screening or within two weeks prior to screening Adequate blood supply defined by transcutaneous oxygen pressure &gt; 20 mmHG and ABI greater than or equal to 0.4 Compliance with nonweight bearing regimen in diabetic patients Compliance with wound care regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Chronic wounds</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Ulcers</keyword>
	<keyword>Arterial bypass</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Diabetic ulcers</keyword>
</DOC>